These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 24443158)

  • 1. Attenuated serotonin transporter association between dorsal raphe and ventral striatum in major depression.
    Hahn A; Haeusler D; Kraus C; Höflich AS; Kranz GS; Baldinger P; Savli M; Mitterhauser M; Wadsak W; Karanikas G; Kasper S; Lanzenberger R
    Hum Brain Mapp; 2014 Aug; 35(8):3857-66. PubMed ID: 24443158
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of SSRI treatment response in major depression based on serotonin transporter interplay between median raphe nucleus and projection areas.
    Lanzenberger R; Kranz GS; Haeusler D; Akimova E; Savli M; Hahn A; Mitterhauser M; Spindelegger C; Philippe C; Fink M; Wadsak W; Karanikas G; Kasper S
    Neuroimage; 2012 Nov; 63(2):874-81. PubMed ID: 22828162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disproportionate Reduction of Serotonin Transporter May Predict the Response and Adherence to Antidepressants in Patients with Major Depressive Disorder: A Positron Emission Tomography Study with 4-[18F]-ADAM.
    Yeh YW; Ho PS; Kuo SC; Chen CY; Liang CS; Yen CH; Huang CC; Ma KH; Shiue CY; Huang WS; Shyu JF; Wan FJ; Lu RB; Huang SY
    Int J Neuropsychopharmacol; 2015 Jan; 18(7):pyu120. PubMed ID: 25568284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Altered interregional molecular associations of the serotonin transporter in attention deficit/hyperactivity disorder assessed with PET.
    Vanicek T; Kutzelnigg A; Philippe C; Sigurdardottir HL; James GM; Hahn A; Kranz GS; Höflich A; Kautzky A; Traub-Weidinger T; Hacker M; Wadsak W; Mitterhauser M; Kasper S; Lanzenberger R
    Hum Brain Mapp; 2017 Feb; 38(2):792-802. PubMed ID: 27770470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Self-transcendence trait and its relationship with in vivo serotonin transporter availability in brainstem raphe nuclei: An ultra-high resolution PET-MRI study.
    Kim JH; Son YD; Kim JH; Choi EJ; Lee SY; Joo YH; Kim YB; Cho ZH
    Brain Res; 2015 Dec; 1629():63-71. PubMed ID: 26459992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Will imaging individual raphe nuclei in males with major depressive disorder enhance diagnostic sensitivity and specificity?
    Pillai RLI; Zhang M; Yang J; Boldrini M; Mann JJ; Oquendo MA; Parsey RV; DeLorenzo C
    Depress Anxiety; 2018 May; 35(5):411-420. PubMed ID: 29365217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serotonergic neurotransmission in the living human brain: a positron emission tomography study using [¹¹C]dasb and [¹¹C]WAY100635 in young healthy men.
    Takano H; Ito H; Takahashi H; Arakawa R; Okumura M; Kodaka F; Otsuka T; Kato M; Suhara T
    Synapse; 2011 Jul; 65(7):624-33. PubMed ID: 21484882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incongruent reduction of serotonin transporter associated with suicide attempts in patients with major depressive disorder: a positron emission tomography study with 4-[18F]-ADAM.
    Yeh YW; Ho PS; Chen CY; Kuo SC; Liang CS; Ma KH; Shiue CY; Huang WS; Cheng CY; Wang TY; Lu RB; Huang SY
    Int J Neuropsychopharmacol; 2014 Oct; 18(3):. PubMed ID: 25522405
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simple and rapid quantification of serotonin transporter binding using [
    Gryglewski G; Rischka L; Philippe C; Hahn A; James GM; Klebermass E; Hienert M; Silberbauer L; Vanicek T; Kautzky A; Berroterán-Infante N; Nics L; Traub-Weidinger T; Mitterhauser M; Wadsak W; Hacker M; Kasper S; Lanzenberger R
    Neuroimage; 2017 Apr; 149():23-32. PubMed ID: 28119137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A positron emission tomography study of the serotonergic system in relation to anxiety in depression.
    Iscan Z; Rakesh G; Rossano S; Yang J; Zhang M; Miller J; Sullivan GM; Sharma P; McClure M; Oquendo MA; Mann JJ; Parsey RV; DeLorenzo C
    Eur Neuropsychopharmacol; 2017 Oct; 27(10):1011-1021. PubMed ID: 28811068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Striatal dopamine D2/3 receptor-mediated neurotransmission in major depression: Implications for anhedonia, anxiety and treatment response.
    Peciña M; Sikora M; Avery ET; Heffernan J; Peciña S; Mickey BJ; Zubieta JK
    Eur Neuropsychopharmacol; 2017 Oct; 27(10):977-986. PubMed ID: 28870407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decreased brainstem and putamen SERT binding potential in depressed suicide attempters using [11C]-zient PET imaging.
    Nye JA; Purselle D; Plisson C; Voll RJ; Stehouwer JS; Votaw JR; Kilts CD; Goodman MM; Nemeroff CB
    Depress Anxiety; 2013 Oct; 30(10):902-7. PubMed ID: 23526784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elevated serotonin transporter binding in major depressive disorder assessed using positron emission tomography and [11C]DASB; comparison with bipolar disorder.
    Cannon DM; Ichise M; Rollis D; Klaver JM; Gandhi SK; Charney DS; Manji HK; Drevets WC
    Biol Psychiatry; 2007 Oct; 62(8):870-7. PubMed ID: 17678634
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regional Differences in Serotonin Transporter Occupancy by Escitalopram: An [
    Kim E; Howes OD; Kim BH; Chon MW; Seo S; Turkheimer FE; Lee JS; Lee YS; Kwon JS
    Clin Pharmacokinet; 2017 Apr; 56(4):371-381. PubMed ID: 27557550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serotonergic dysregulation is linked to sleep problems in Parkinson's disease.
    Wilson H; Giordano B; Turkheimer FE; Chaudhuri KR; Politis M
    Neuroimage Clin; 2018; 18():630-637. PubMed ID: 29845011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 123I-ADAM binding to serotonin transporters in patients with major depression and healthy controls: a preliminary study.
    Newberg AB; Amsterdam JD; Wintering N; Ploessl K; Swanson RL; Shults J; Alavi A
    J Nucl Med; 2005 Jun; 46(6):973-7. PubMed ID: 15937308
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Altered serotonin transporter binding potential in patients with obsessive-compulsive disorder under escitalopram treatment: [11C]DASB PET study.
    Kim E; Howes OD; Park JW; Kim SN; Shin SA; Kim BH; Turkheimer FE; Lee YS; Kwon JS
    Psychol Med; 2016 Jan; 46(2):357-66. PubMed ID: 26423910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Higher serotonin transporter availability in early-onset obsessive-compulsive disorder patients undergoing escitalopram treatment: A [
    Lee J; Kim BH; Kim E; Howes OD; Cho KIK; Yoon YB; Kwon JS
    Hum Psychopharmacol; 2018 Jan; 33(1):. PubMed ID: 29210107
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lower availability of midbrain serotonin transporter between healthy subjects with and without a family history of major depressive disorder - a preliminary two-ligand SPECT study.
    Hsieh PC; Chen KC; Yeh TL; Lee IH; Chen PS; Yao WJ; Chiu NT; Chen CC; Liao MH; Yang YK
    Eur Psychiatry; 2014 Sep; 29(7):414-8. PubMed ID: 24439516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Altered interregional correlations between serotonin transporter availability and cerebral glucose metabolism in schizophrenia: A high-resolution PET study using [
    Kim JH; Kim JH; Son YD; Joo YH; Lee SY; Kim HK; Woo MK
    Schizophr Res; 2017 Apr; 182():55-65. PubMed ID: 27760700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.